Efgartigimod Subcutaneous Injection Approved in China for the Treatment of Generalized Myasthenia Gravis
On July 16, 2024, the news of China ZaiLab announced that the national drug supervision and administration (NMPA) has approved the new biological products and wale ®'s application for marketing authorisation. This product is a kind of subcutaneous injection dosage forms, a bottle containing Edgar moder 1000 mg (5.6 ml), it will serve as a complementary therapy, combined with conventional treatment drugs, to treat the acetylcholine receptor (AChR) antibody testing positive for adult body in patients with myasthenia gravis (gMG) group.
Igatimod, as a novel therapeutic drug, marks a major breakthrough in the field of FcRn inhibitors worldwide. The drug is designed to fight the autoimmune diseases mediated by antibodies. In January 2021, introduced ZaiLab Argenx from companies in this innovative drugs, and get the greater China region in China to Edgar moder exclusive development and commercial rights and interests. By July 2023, the NMPA had approved early Edgar moder intravenous injection of biological products listed licensing applications, application laid a solid foundation for the subsequent treatment.
The approved Edgar moder subcutaneous injection dosage forms, behind it is relying on the worldwide to 3) ADAPT - SC positive results of clinical trials. The study showed that by subcutaneous injection of Edgar maud, not only can copy a comparable to those of intravenous curative effect, and excels in safety.
With the approval of the subcutaneous form of igammod, there are now more treatment options available for those with gMG in adults, which undoubtedly increases their flexibility in disease management. This progress is also expected to greatly promote the effect of disease treatment for patients, bringing significant improvements in their lives.
2026-10-07
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
“Soaring Sulfuric Acid, Tightening Ore Supplies”: The High-Stakes Battle Behind the Titanium Dioxide Price Surge
-
Egypt’s Chemical Surge: $9.4 Billion Export Boom Signals Industrial Powerhouse Rise
-
Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28
-
“Milk Sugar 2.0” Cleared for Takeoff: EU Greenlights Next-Gen Human-Identical Oligosaccharide for Infant Nutrition
-
Aekyung Chemical Plans to Sell Its Ningbo Subsidiary
-
Eastern Shenghong Projects First-Half Profit of 5 Billion Yuan – A Collective Turnaround for the Four Major Private Refiners? Is the Chemical Sector Rebounding?
-
Tinci Materials Calls Off 2.65 Billion Yuan Project as Electrolyte Giant Shifts Strategy
-
Geno and Sojitz Collaborate to Accelerate the Commercialization of Nylon 6
-
Behind Japan's Tungsten Hexafluoride Crisis: Can China's Electronic Specialty Gases Seize a New Opportunity?
-
BASF's Zhanjiang Integrated Site Reaches Major Milestone: Butyl Acrylate Production Commences Ahead of Schedule, Steam Cracker Completes Mechanical Completion
Recommend Reading
-
Asia’s Plastics Chain Faces a Shock: Tight Naphtha Supply Drives Up Polymer Costs
-
German Chemical Sentiment Hits a Three-Year Low: Supply Disruption Amplifies Pressure on European Manufacturing
-
The Last 10% Tariff Trap: A New Chapter in U.S.–China Negotiations on “Fentanyl Tariffs”
-
China's National Narcotics Control Commission Issues Important Notice: Beware of These 8 Chemicals Being Diverted for Drug Production
-
Dietary Supplement Listing Debate Puts Nutrition Ingredients Under a Brighter Spotlight
-
In March, the Chinese marine fuel market saw a significant increase
-
Business Society’s Market Outlook for Acrylonitrile on September 7, 2026: Volatile
-
Business Society’s Market Outlook for LLDPE on September 7, 2026: Volatile
-
October China Soda Ash Market Trend Consolidates
-
Business Society’s PVC Market Outlook on September 7, 2026: Relatively Strong Fluctuations